The anti-melanoma monoclonal antibody HMB45 is widely used in diagnostic pathology owing to its great specificity and sensitivity in identifying pigmented tumors such as malignant melanoma. However, little is known regatding the nature of the anagen(s) recognized by this antibody. In the obsermtions reported here, the HMB45-defined antigen was idendfied in another pigmented tissue, the retinal pigment epithelium (RPE). A series of immunocytochemical studies demonstrated transient reactivity of the prenatal and idintile human RPE with antibody HMB45; adult RPE is non-reactive with the antibody. By immunoelectron microscopy, the antibody was demonstrated to react with immature melanosomes. &-treatment of deparafliized tis-
Introduction
HMB45 defines a melanoma-and melanocyte-specific antigen (7) which has been demonstrated to have important utility in the diagnosis of poorly daerentiated human tumors (4,7,19,27). The antibody binds to antigen present in the cytoplasm of neoplastic melanocytic cells, including junctional nevi and malignant melanoma, but not present in intradermal nevi or normal adult melanocytes (7) . HMB45 also labels melanocytes in fetal skin, beginning at a gestational age of approximately 50 days (8, 9) . This distribution of cells and tissues recognized by HMB45 suggests that it binds to an oncofetal antigen.
Little is known about the nature of the antigen or antigens recognized by HMB45. Light microscopic studies have shown that the HmS-defiied antigen resides in the cytoplasm, but specific subcellular sites of localization have not been established. Previous studies have suggested that HMB45 immunoprecipitates a 10 KD protein from extracts of malignant melanoma; however, the absence of t h i s immunoreactive peptide in non-neoplastic melanocytes has not been verified (6) . Comparative sue sections with neuraminidase completely eliminated HMB45 immunoreactivity, suggesting that the antigen@) recognized is a sialated glymnjugate. Mannosidase or N-acet y l g l u d d a s e pre-treatment had no effect on immunoreactivity. Thus, HMB45 may identify an oncofetal antigen presentincutaneousmelanocytes,RPE, andmelanomacells, and changes in immunoreactivity with maturation or malignant transformation may be a function of post-translational modification. ( J Hisrochem Cytochun 40:207-212, 1992) KEY WORDS: HMMI; Melanoma; Oncofctal antigen; Retinal pigment epithelium; Melanocytes; Pre-melanosome; Human; Immunocytochemistry. lated from malignant and non-neoplastic melanocytic cells have been limited, in part, by the inability to isolate large quantities of the latter for biochemical analyses.
In this study, HMB45 immunoreactivity with human retinal tissues was examined at various stages of prenatal and postnatal development. The antibody was demonstrated to label pre-and immature melanosomes in retinal pigment epithelium (RPE) from fetuses and neonates but not from adults. Evidence is provided that the antibody reacts with a glycoconjugate. On the basis of these observations, we suggest that the oncofetal pattern of expression exhibited by these antigens may be due to changes in glycosylation associated with ontogenesis and oncogenesis.
Materials and Methods
F'"ent of Fetal and Adult Tissues. Fourteen human tissue spcch e n s were utilized in this study ('Iible 1). Eleven prenatal eyes were obtained from human abortuses, stillborn idants, and surgical pathology specimens collected by the Central Laboratory for Human Embryology and the Department of Pathology of the University of Washington. Posterior segments of eycs from a 14-year-old and a 9-month-old individual were obtained from the Lions Eyc Bank at the University of Washington. Early embryos (less than 60 days post conception) were staged according to gross and histologid landmarks published by O'Rahilly and Muller (18) . In preparation for immunocytochemical labeling studies, the specimens were rem m d and immediately immersion-fixed in methacam (methanoLCat-KAPUR, BIGLER, SKELCY, GOWN noy's) fiitive for a minimum of 2 hr; one 44-day embryo was obtained retrospectively after fixation in 10% neutral buffered formalin.
Immunocytochemistry. All tissues were immunostained with HMB45 ascites fluid (at 1:1000 dilution) or supernatant fluid (at 1:200 dilution). Localization was via an avidin-immunodkaline phosphatase method with "Vector Red" (Vector Laboratories; Burlingame, CA) as the chromogen (7). This yielded a red reaction product which was critical to the success of immunolocalization in heavily pigmented tissues such as RPE.
Immu"n Micrompy. The embedding and indirect immunogold labeling methods described by Kapur and Johnson (12) were employed. Eyes from two fetuses (65 and 74 days post ovulation) were bisected and one half of each was fixed in half-strength Karnovsky's fixative, followed by embedding in Lowicryl K4M (Polysciences; Warrington, PA). Thin (100nm) sections were collected on nickel grids, rinsed twice with 1% bovine serum albumin (BSA) in PBS at pH 7.4 (PBSIBSA), and incubated for 30 min in purified HMM5 antibody diluted 1:lOO in PBSIBSA. After two 15min rinses with PBSIBSA, the sections were incubated for 30 min in goldconjugated goat anti-mouse IgG (10-nm size) (Janssen Biochemica; Beerse, Belgium) diluted 1:lOO in PBSIBSA. Finally, the sections were rinsed three times for 10 min each in PBS, followed by a brief rinse with distilled water. As a control for specificity, PBSIBSA was substituted for the primary antibody. The remaining half of each eye was post-fmed with 1% osmium tetroxide and embedded in plastic for conventional ultrastructural studies. In all of the electron microscopic studies, the sections were stained after immunolabeling with 2.5% uranyl acetate ( 5 min) and Reynolds' lead stain (5-10 sec) (22) . Plastic-embedded sections were stained with the two reagents for 10 and 5 min, respectively. The sections were examined and photographed with a Phillips 410 electron microscope.
Glycosidase Studies. For glycosidase studies, deparaffinized tissue sections from two fetal eyes (lible 1; Specimens H-10,176 and H-10,163) were incubated with one afthe following enzymes More incubation with HMB45: neuraminidase (Sigma Biochemicals, St Louis, MO; 0.2 Ulml), N-acetylglucosaminidase (Sigma; 0.75 UIml), mannosidase (Sigma; 0.2 Ulml) with appropriate buffer controls. Glycosidase treatments were for intervals ranging from 6-24 hr at 37'C.
Results
The studies presented here show that HMB45 recognizes an antigen or antigens that are expressed normally in the fetal and neonatal human RPE. In the 32-day embryo, immunolabeling by HMB45 was detected in primitive retinal epithelial cells at the periphery of the optic cup (Figures la and lb); immunoreactivity was not detected in any other tissues at this stage. The appearance of HMB45positive cells preceded the development of pigment granules recognizable by light microscopy, which arise about embryonic day 37 (18) . At later stages of fetal development, the HMB45-defined antigen was expressed in the cytoplasm of the entire RPE, as well as in pigmented epithelial cells in the ciliary body, iris, and melanogenic fibrocytes in the uveal stroma (Figures IC and Id). The intensity of the labeling appeared to be greatest in the apical cytoplasm of the epithelial cells. This pattern of immunostaining persists into infancy but disappears before adulthood ( Figure lf) .
The earliest retina examined by electron microscopy was from a fetus with an estimated gestational age of 65 days. At this stage the RPE was fairly well differentiated and the cells contained many pigment granules in various stages of maturation (Figure 2a ). Premelanosomes have ovoid profiles with lamellated contents. Melanocyte maturation is associated with progressive accumulation of electron-dense material within the pigment granules until they have a homogeneous dense appearance. By immunogold labeling at the ultrastructural level, HMB45 was found to label the matrix of premelanocytes and immature melanosomes in the fetal RPE ( Figures  2b and 2c ). Although the density in photomicrographs of condensed matrix in mature melanosomes was comparable to that of the gold particles, sufficient difference in electron density was observed at the microscope to be confident that label was not associated with fully mature melanosomes or other organelles. Similar ultrastructural features were evident in ocular tissue from a 75-day fetus (not shown). Immunoreactivity at the light microscopic level, on deparaffinized tissue sections, was completely abolished by 6-hr pretreatment of sections with neuraminidase, an enzyme that specifically cleaves terminal sialic acid residues ( Figure Ig) . In contrast, treatments with mannosidase ( Figure Ih) , N-acetylglucosaminidase, or buffer alone for periods up to 24 hr have no dfect on tissue immunoreactivity for HMB45.
Discussion
The monoclonal antibody HMB45 is known for its clinical usefulness as a highly specific marker for neoplastic melanocytes, particularly melanoma. We have made several novel observations concerning HMB45 immunoreactivity in the developing human eye.
First, antigen recognized by the antibody is transiently expressed in fetal and neonatal RPE. Second, this immunoreactivity is directed against antigens within pre-and immature melanosomes. Third, the epitope recognized by the antibody is sensitive to neuraminidase.
The transient expression in RPE of antigens recognized by HMB45 is similar to that observed in cutaneous melanocytes (8, 9) . Unlike cutaneous melanocytes, which arise from migrating neural crest cells, RPE develops from the optic cup, an evagination of the . 
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b neural tube, but these two cell types both express melanin as the principal granule-associated pigment. HMB45 immunoreactivity in the W E , present at embryonic day 32, appears earlier than in cutaneous melanocytes, which are not recognized by the antibody until embryonic day 50 (9). In both cell types the expression of antigen precedes the appearance of mature melanosomes by sev- eral days (9,18) and is lost sometime between infancy and adulthood; insufficient numbers of specimens in the latter group precluded more precise identification of the time of disappearance of this antigen from RPE.
Recently, Pettinato et al. (20) reported HMB-45 immunoreactivity in the RPE of five out of five formalin-fixed, normal adult human eyes, although no photomicrographs to demonstrate this result were published. Their observations conflict directly with our own findings of no detectable immunoreactivity in the two oldest patients in our study (14 and 39 years). The reason for this discrepancy is not clear; however, technical differences between the two studies may be important. First, supernatant, rather than ascites fluid, was used in our study, as the latter has been shown to lack tissue specificity (3). It is not clear which type of antibody preparation was used by Pettinato and colleagues. Second, in contrast to Pettinato et al. (20) , we made a deliberate effort to utilize methacarn-fmed specimens since, in our hands, nonspecific HMB-45 staining, which can be a significant problem in formalin-fixed tissue, is not a problem with methacam fixation. We believe our examination of an adult eye with uveal melanoma (Figure lf) is particularly compelling evidence for lack of immunoreactivity in methacam-fixed pigment epithelium, since the melanoma cells provide an internal positive control for HMB45. Resolution of this controversy is important, since persistent HMB45 immunoreactivity in the RPE would be distinctly different from the oncofetal pattern of expression seen in cutaneous melanocytes.
Collectively, our observations are consistent with the specificity the antibody exhibits for certain melanogenic cell types and imply ontogenic and oncogenic changes in the composition of melanosomes. In the human and murine RPE, the relative numbers of pre-melanosomes and immature melanosomes decrease markedly during late gestation and early infancy, such that primarily mature melanosomes are present in older individuals (16J7). The natural disappearance ultrastructurally of pre-and immature melanosomes probably reflects developmentally programmed changes in the composition of melanosomal matrix, which eventually include complete loss of HMB45 immunoreactivity. Morphological, biochemical, and histochemical differences between melanosomes in benign and malignant melanocytic cells, including differences in premelanosomal ultrastructure, have also been described (10,13,24) .
Our experiments suggest that the epitope recognized by HMB45 is, at least in part, the oligosaccharide side chain of a sialated glycoconjugate. Given this evidence, it is possible that alterations in protein glycosylation account for the dramatic appearance and disappearance of HMB45 immunoreactivity during various onto-genic and pathogenic states of melanogenic cells. Imakowa (11) has shown that carbohydrate modifications of glycoproteins in melanoma cells affect the subcellular localization of these molecules within pre-melanosomes and may regulate melanogenesis. Similar ontogenic alterations in post-translational modification have been demonstrated in other systems, where they are thought to correlate with a more terminally differentiated state (5.23). In addition, changes in glycosylation patterns correlate with malignant transformation in many cell types, including melanoma. For example, Kohchiyama et al. (13) demonstrated that specific lectin binding sites are unmasked by neuraminidase treatment of malignant melanocytes, but not of benign intradermal nevi or normal adult melanocytes. Therefore, neuraminidase treatment has the dual effect of eliminating HMB45 binding sites and exposing novel lectin binding sites in melanoma cells. We are presently investigating the possibility that these lectins interact with the desialated form of the antigen recognized by HMB45.
Many antibodies have been described that exhibit various degrees of specificity for malignant melanoma and melanocytes (1,14,15,  21,25,26) ; some of the latter also react with fetal melanocytes (1,25,26) . Unfortunately, relatively few of the antigens recognized by other "melanoma-specific'' antibodies have been well characterized. HMB45 differs from most of these antibodies in that it does not appear to react with any non-melanocytic tissues, and its expression in adults is confined to neoplastic melanocytic cells. Scattered reports of non-melanoma tissues reacting with HMB45 (2) probably reflect quality control problems with the commercial preparations of this antibody, as supernatant fluids of HMB45 do not manifest any such crossreactivity (3). The observation that HMB45 reacts with glycosyl residues suggests the possibility that many of these antibodies recognize different post-translational modifications of identical proteins. Differences in protein modification (e.g., glycosylation) rather than protein expression may account for the existence of so many antibodies with slightly different patterns of selectivity for various histological types of benign and malignant melanocyte populations. dy, for helping toprepare triruesforsome ofthe electron mimscopicstudiv. 
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